| Revenue growth | Q2 +19.6%; H1 +19.4% YoY |
|---|---|
| Margins | Q2 EBITDA margin 32.1% vs 30.7%; H1 31.6% vs 29.7% |
| Demand visibility | Growing demand for specialized, high-complexity testing |
| Management confidence | Upbeat: resilient performance, well positioned |
Growth
Q2 revenue +19.6% YoY, EBITDA +25.1%, PAT +27.5%. H1 FY27 revenue Rs 1,672 Cr (+19.4%), PAT Rs 364 Cr (+27.3%).
Outlook
No explicit numeric guidance. Strategy focuses on AI, precision diagnostics, international business, M&A and rural expansion.
Risks
No specific headwinds quantified; management stresses balancing growth investments with profitability.
Last quarter's promises, checked
Delivered
- Guided mid-teens revenue growth → Q2 +19.6%, H1 +19.4% (= BEAT)
- Guided EBITDA margin 27%-28% → Q2 32.1%, H1 31.6% (= BEAT)
- Guided patient volume growth 6%-7% → Q2 +9.0% (= BEAT)
Investor Presentation filed with NSE, NSE: LALPATHLAB. Summary written with AI assistance from the document.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹2,045.00
- Market cap
- ₹34,325 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 58.8×Sector 53.8×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Management Change
Dr. Lal Path Labs appointed Ms. Vasuta Agarwal as an additional Non-Executive Independent Director for three years from 4 November 2026. Her appointment is subject to member approval by postal ballot.
- Execution
- 36 months from 04-11-2026
Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Dr. Lal Pathlabs Dividend
Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.
Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹193.9 Cr · +27.4% YoY
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
- Value
- ₹30.30 Cr